Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

January 19, 2024

https://www.prnewswire.com/news-releases/chemomab-presentation-at-acr-convergence-2023-provides-further-support-for-key-role-of-its-ccl24-target-in-the-pathogenesis-of-systemic-sclerosis-301990243.html

–Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension —

Read more at prnewswire.com

Related news for (CMMB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.